MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
WARREN, N.J., Jan. 18, 2011 /PRNewswire/ -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® drug delivery technology, filed an amended patent infringement and false marking lawsuit today against BioDelivery Sciences International, Inc. (NASDAQ: BDSI; "BDSI"), MEDA Pharmaceuticals Inc. ("MEDA"), and Aveva Drug Delivery Systems, Inc. ("Aveva") in the United States District Court for the District of New Jersey.
MonoSol Rx's complaint asserts that BDSI, MEDA, and Aveva's manufacture, marketing, and sale of the OnsolisTM film products infringe MonoSol Rx's United States Patent No. 7,824,588 related to methods of making drug-containing films. As one of the leaders in the development and commercialization of film pharmaceutical and over-the-counter drug products, MonoSol Rx has an extensive technology patent portfolio.
MonoSol Rx filed its patent infringement claim against these defendants initially in November, 2010. Today's amended complaint adds an additional false marking claim with respect to U.S. Patent No. 5,800,832.
MonoSol Rx is represented in the action by Howrey LLP.
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence.
MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator or other specialty pharma companies that can sell-in and manage product sales and marketing. PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).For existing and future partners, PharmFilm® formulations can also represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. For press releases and other company information visit www.monosolrx.com